转移性尿路上皮癌：我们是否已踏上个体化医学之路？
Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?
机构信息
Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, 10124 Turin, Italy.
Department of Medical Oncology, Cardinal Massaia Hospital, 14100 Asti, Italy.
出版信息
Cells. 2022 May 11;11(10):1614. doi: 10.3390/cells11101614.
Abstract
Urothelial cancer is a lethal malignancy characterized by a wide diffusion in Western countries due to a larger exposure to known risk factors, such as aromatic amines, tobacco smoke and benzene [...].
摘要
尿路上皮癌是一种致命的恶性肿瘤，在西方国家由于广泛接触已知的危险因素，如芳香胺、烟草烟雾和苯[... ]，其发病率较高。
相似文献
1
Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?
Cells. 2022 May 11;11(10):1614. doi: 10.3390/cells11101614.
2
New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine?
Crit Rev Oncol Hematol. 2022 Jun;174:103682. doi: 10.1016/j.critrevonc.2022.103682. Epub 2022 Apr 11.
3
Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
Expert Rev Anticancer Ther. 2022 May;22(5):449-455. doi: 10.1080/14737140.2022.2069563. Epub 2022 Apr 26.
4
Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy.
Front Immunol. 2023 Aug 22;14:1258388. doi: 10.3389/fimmu.2023.1258388. eCollection 2023.
5
Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Jpn J Clin Oncol. 2024 Mar 9;54(3):329-338. doi: 10.1093/jjco/hyad170.
6
Enfortumab vedotin - next game-changer in urothelial cancer.
Expert Opin Biol Ther. 2021 Jul;21(7):801-809. doi: 10.1080/14712598.2021.1865910. Epub 2020 Dec 27.
7
The biology and rationale of targeting nectin-4 in urothelial carcinoma.
Nat Rev Urol. 2021 Feb;18(2):93-103. doi: 10.1038/s41585-020-00394-5. Epub 2020 Nov 25.
8
Emerging personalized approaches for the management of advanced urothelial carcinoma.
Expert Rev Anticancer Ther. 2012 Dec;12(12):1537-43. doi: 10.1586/era.12.141.
9
Use of enfortumab vedotin in an HIV-positive patient with urothelial carcinoma.
J Oncol Pharm Pract. 2022 Jul;28(5):1226-1229. doi: 10.1177/10781552221074309. Epub 2022 Jan 19.
10
Current Therapy for Metastatic Urothelial Carcinoma.
Hematol Oncol Clin North Am. 2021 Jun;35(3):469-493. doi: 10.1016/j.hoc.2021.02.010. Epub 2021 Apr 10.
引用本文的文献
1
ADME gene-driven prognostic model for bladder cancer: a breakthrough in predicting survival and personalized treatment.
Hereditas. 2025 Mar 19;162(1):42. doi: 10.1186/s41065-025-00409-4.
2
Discovery of a T cell proliferation-associated regulator signature correlates with prognosis risk and immunotherapy response in bladder cancer.
Int Urol Nephrol. 2024 Nov;56(11):3447-3462. doi: 10.1007/s11255-024-04086-6. Epub 2024 May 24.
3
Urothelial Carcinoma With Bone Metastasis Mimicking Sciatica: A Common Neoplasm With an Uncommon Presentation.
Cureus. 2024 Feb 29;16(2):e55259. doi: 10.7759/cureus.55259. eCollection 2024 Feb.
本文引用的文献
1
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on / mRNA Expression.
J Clin Oncol. 2023 Jan 20;41(3):629-639. doi: 10.1200/JCO.21.02303. Epub 2022 Oct 14.
2
New Directions and Challenges in Targeted Therapies of Advanced Bladder Cancer: The Role of FGFR Inhibitors.
Cancers (Basel). 2022 Mar 10;14(6):1416. doi: 10.3390/cancers14061416.
3
Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside.
Cells. 2022 Feb 25;11(5):803. doi: 10.3390/cells11050803.
4
New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond.
Cells. 2022 Jan 21;11(3):357. doi: 10.3390/cells11030357.
5
Metastatic Urothelial Cancer: a rapidly changing treatment landscape.
Ther Adv Med Oncol. 2021 Sep 30;13:17588359211047352. doi: 10.1177/17588359211047352. eCollection 2021.
6
Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives.
Cancers (Basel). 2021 Aug 31;13(17):4411. doi: 10.3390/cancers13174411.
7
Urothelial carcinoma in the era of immune checkpoint inhibitors.
Immunotherapy. 2021 Aug;13(11):953-964. doi: 10.2217/imt-2021-0042. Epub 2021 Jun 29.
8
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Lancet Oncol. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26.
9
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
Lancet Oncol. 2021 Jul;22(7):919-930. doi: 10.1016/S1470-2045(21)00147-9. Epub 2021 May 26.
10
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Lancet Oncol. 2021 Jun;22(6):872-882. doi: 10.1016/S1470-2045(21)00094-2. Epub 2021 May 12.
Zotero 插件